WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Cardea Services
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
Medical
BioAgilytix | August 17, 2021
BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...
Diagnostics
Lucid Diagnostics | March 25, 2022
Lucid Diagnostics Inc., a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc, announced that investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center had enrolled their first patient in a Department of Defense ("DoD")- Katarina B. Greer, M.D., an associate professor of medicine at Case Western Reserve University School of Medicine in Cleveland, is the lead investigator of the research. Lucid supplies the...
Cell and Gene Therapy
Biocytogen | June 23, 2021
Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...
Genelux Corporation | September 29, 2021
Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...
Video
Medical, Industry Outlook
Whitepaper
Industrial Impact, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE